Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

NCT02728934 · clinicaltrials.gov ↗

COMPLETED

Status

1279

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid

Interventions

BIOLOGICAL: Golimumab Intravenous (IV)
BIOLOGICAL: Infliximab
BIOLOGICAL: Biosimilar Infliximab

Sponsor

Janssen Scientific Affairs, LLC